



**BEIJING INTERNATIONAL
HEALTHCARE INDUSTRY FORUM
2010
AGENDA**

The Secretariat of the Organizing Committee
The 14th Beijing International Healthcare Industry Forum
October, 2010



INVITATION

Dear Mr. /Ms. _____,

The Beijing International Healthcare Industry Forum (HIF) 2010, co-hosted by **Administrative Office of the National Key Program for New Drug Research and Development** and **Beijing Municipal Science and Technology Commission**, organized by **Beijing Pharma and Biotech Center (BPBC)**, will be held on Oct. 25th~27th, 2010 at Beijing International Hotel Convention Center.

The year of 2010 is the beginning of the Leap-Forward Development Initiative for Beijing pharmaceutical and biotechnological industry. By promoting a number of strategic drivers, such as technology transfer, financial incentives, industry clusters construction, success will be realized. Beijing formed an innovative network that shares the same vision and resource management which helped it be in a leading position to collaborate with Governmental agencies and Academic institution. Beijing is now becoming the global pharmaceutical and biotech innovative city where pharmaceutical and biotechnological industry is taking place and building Beijing as the “Global City” of choice.

The HIF 2010 theme is “Leap-Forward Development, Building Beijing as a Global Innovative City”. The HIF features plenary session, theme summits, “one-on-one partnering meeting” and exhibition. Hot topics to be discussed include biopharmaceutical industry Leap-Forward Development, new trends of Chinese biopharmaceutical industry, the CMO & CRO industry, overseas talents’ opportunities, the development in science parks and clusters, technology transfer, investment and financing. You will have an excellent opportunity to learn more about new policies, key incentive measure and major achievements in Beijing pharmaceutical and biotechnological industry. You will also have a chance to meet potential partners and decision makers from China and abroad.

The HIF, dates back to 1997, is a global pharmaceutical and biotechnological industry annual conference, held for 13 years with over 7,000 attendees. Based on feedback received, the conferences exceeded expectations of participants and were considered very successful.



Following the HIF motto- “analyze the industry situation, solve developing problems and construct a healthy future”, the HIF has been dedicated to bringing together VPs, CEO's and executives from the Global 50 companies and Top 300 Chinese companies to exchange ideas and identify opportunities for collaborations. The HIF is now recognized as the platform that brings global participants together to bridge western and Chinese biopharmaceutical industry.

We sincerely would like to invite you to attend the 14th HIF as a keynote speaker, to join the discussion on opportunities and challenges for the biopharmaceutical industry within the theme Leap-Forward Development. We will be pleased to have you join other worldwide decision makers from biopharmaceutical companies, academic institutions, industry and governments. We are confident that the HIF will be successful because of your presence and participation!

We look forward to seeing you in Beijing!

Sincerely yours,

Dr. Frank L. Douglas

Co-Chair of the Organizing Committee of the
14th HIF (2010)

President and CEO of the BioInnovation
Institute in Akron, Chief Scientific Adviser of
Bayer Healthcare

Dr. Yan Aoshuang

Co-Chair of the Organizing Committee of
the 14th HIF (2010)

Director-General of Beijing Municipal
Science and Technology Commission



Organizing Committee

Chairman:

Frank Douglas	President and CEO of the BioInnovation Institute in Akron, Chief Scientific Adviser of Bayer Healthcare
He Wei	Director of the Science and Technology Education Department of Ministry of Health, and Director of the Administrative Office of the National Key Program for New Drug Research and Development
Yan Aoshuang	Director-General of Beijing Municipal Science and Technology Commission

Members:

Nahed Ahmed	Global R&D Vice President of Amgen
Mervyn Turner	Chief Strategy Officer of Merck and Senior Vice President of Emerging Markets of Merck Research Laboratories
Jean-Jacques Garaud	Global Head of Research and Early Development of Roche
Lee E. Babiss	Executive Vice President of PPD
Stephen Henry Friend	President of Sage Bionetworks, former SVP of Merck
Scott Smith	Head of Inflammation and Immunology Franchise of Celgene Corporation
Joseph D. Panetta	CEO of BIOCOM
Anthony J. Dennis	President and CEO of BioOhio
Christian Stein	CEO of Ascenion GmbH Technology Transfer Company (Germany)
Francis Tse	Global Vice President of Drug Metabolism and Bio-analysis of Novartis
Alan Paau	Vice-chancellor of Cornell University, President of the Research Foundation at Cornell University, and Executive Director of the Technology Transfer Center at Cornell University
Paul Paolatto	Director of the Technology Transfer Center at University of Western Ontario



Zheng Hong	Director of the Department of Pharmaceutical Policy and Essential Drug System under the Ministry of Health, P.R.C
Yin Hongzhang	Chief of the Biological Product Division of the Drug Registration Department under State Food and Drug Administration
Zhang Yanyou	Deputy Director of Beijing Municipal Commission of Development and Reform
Zhu Yan	Director of Beijing Municipal Commission of Economy and Information Technology
Cheng Yuhua	Deputy Director of Beijing Municipal Commission of Commerce
Yang Weiguang	Deputy Director of Beijing Municipal Science and Technology Commission
Li Baowei	Deputy Director of Beijing Investment Promotion Bureau
Guo Hong	Director of the Administrative Committee of Zhongguancun Science Park
Cong Luoluo	Director of Beijing Drug Administration
Zhao Xinxin	Deputy Director of Beijing Economic-Technological Development Area
Lei Ting	Director of Beijing Pharma and Biotech Center
He Fuchu	Head of Academy of Military Medical Sciences and Academician of Chinese Academy of Sciences
Wang Xiaodong	Director of National Institute of Biological Science, Beijing and Academician of the US National Academy of Sciences
Shi Yigong	Dean of College of Life Sciences at Tsinghua University, and professor of Tsinghua University
Chen Zhinan	Professor of The Fourth Military Medical University, and Academician of Chinese Academy of Engineering
Luo Yongzhang	Specially-invited professor of Cheung Kong Scholars Programme, and professor of Tsinghua University
Cheng Jing	Professor of Tsinghua University, and Academician of Chinese



	Academy of Engineering
Wang Yu	Director of Chinese Center for Disease Control and Prevention
Wang Junzhi	Deputy Director of National Institute for the Control of Pharmaceutical and Biological Products
Shen Xinliang	Director of National Vaccine & Serum Institute, and Chairman of the Executive Committee of ABO
Yu Mingde	President of Chinese Pharmaceutical Enterprises Association
Wei Huacheng	President of Medical & Pharmaceutical Commercial Association All-China Federation of Industry & Commerce, and Chairman of Beijing Pharmaceutical Group Co., Ltd
Wang Jianji	President (2009-2010) of Sino-American Pharmaceutical Professionals Association
Yu Jun	Board Chairman of Zhongguancun Development Group
Wang Lifeng	Party Secretary and Vice Board Chairman of China National Pharmaceutical Group Corporation
Mei Qun	GM of Beijing Tongrentang Group Co., Ltd



Hosts:

Beijing Municipal Science and Technology Commission

Administrative Office of the National Key Program for New Drug Research and Development

Organizers:

Chinese Pharmaceutical Enterprises Association (CPEA)

Medical and Pharmaceutical Commercial Association, All-China Federation of Industry and
Commerce (CMP)

Beijing Pharma and Biotech Center (BPBC)

Supporters:

State Food and Drug Administration

Beijing Municipal Commission of Development and Reform

Beijing Municipal Commission of Economy and Information Technology

Beijing Municipal Commission of Commerce

The Administrative Committee of Zhongguancun Science Park

Beijing Investment Promotion Bureau

Beijing Banking Regulatory Bureau under China Banking Regulatory Commission

Beijing National Bio-industrial Base

The Banking Management Department of People's Bank of China

Chinese Academy of Medical Sciences

Academy of Military Medical Sciences

China Academy of Chinese Medical Sciences

National Institute for the Control of Pharmaceutical and Biological Products

Beijing Pharmaceutical Profession Association

Beijing Bio-Engineering Society

Beijing Pharmaceutical Group Co., Ltd

Youcare Pharmaceutical Group Co., Ltd

Beijing Wantai Biological Pharmacy

Beijing TRT (Group) Co., Ltd

Beijing TRT Pharmaceutical Co., Ltd



Co-Organizers:

Beijing Industry-University- Institute Alliance for New Drug Creation

Beijing Alliance of Medical Device Innovation

Alliance of Bio-Box Outsourcing, China (ABO)

Beijing Zhongguancun Association of Biotech and New Medicine Enterprises

Antibody Industrial Technology Innovation (Northern) Strategic Alliance

Overseas Partners:

Biotech Association of Southern California (BIOCOM)

Biotech Association of Ohio (BioOhio)

Technology Transfer Centre at University of Western Ontario (WorldDiscovery)

Sino-American Pharmaceutical Professionals Association (SAPA)

American-Chinese Biopharmaceutical Entrepreneurs Association (ACBEA)

Toulouse cancer-bio-sante

BayHelix



Schedule

The 14th Beijing International Healthcare Industry Forum

Oct 24, 2010 (Sunday)				
9:30-17:30	Beijing SAPA President Forum—Improve Environment to Attract Investment and Promote Leap-forward Development Conference Center, Beijing International Hotel			
Oct 25, 2010 (Monday)				
09:00-14:00	Registration Floor 1, Conference Center, Beijing International Hotel			
Plenary Session—Leap-forward Development to Build Beijing into a Global Innovative City				
14:30-15:00	Opening Ceremony		Purple Palace A, Floor 3	
15:00-17:40	Plenary Session		Purple Palace A, Floor 3	
18:00-20:00	Reception Banquet (Invited Only)		Purple Palace B, Floor 3	
Oct 26, 2010 (Tuesday)				
09:00-12:00	09:00-17:00	09:00-17:00	09:00-17:40	9:00-16:30
Summit on Beijing Leap-forward Development program for Biopharmaceutical Industry(G20)	The 4 th Technology Transfer Summit	TCM Industry Development Seminar	Diagnostic Industry Seminar	ABO Global Partnership Meeting 2010
18:30-20:00	Reception Dinner for Gold Sponsors (Invited Only)			
Oct 27, 2010 (Wednesday)				
13:30-17:50	09:00-17:10	13:30-17:30	13:30-18:00	09:00-16:00
Biopharmaceutical Policies Interpretation Seminar	Antibody Industry Development Seminar	Medical Imaging Industry Seminar	Summit on the Global Trends and Opportunities for Generic Drugs	The 3 rd BioCapital Summit
18:30-20:00	Reception Dinner for Gold Sponsors (Invited Only)			
Oct 28, 2010 (Thursday)				
09:00-11:00	Tour			



Program

The 14th Beijing International Healthcare Industry Forum

Oct 25, 2010 (Monday)

Opening Ceremony and Plenary Session

Venue: Conference Center, Beijing International Hotel

Tenet:

The HIF 2010 will be under the theme of “Leap-Forward Development, Building Beijing as a Global Innovative City”, to analyze the challenges and opportunities of Beijing bio-pharmaceutical industry. The keynote speeches will center on topics as the global development trend for bio-pharmaceutical industry under the post-crisis era, the strategies for China pharmaceutical enterprises to reply to the new changes and the new opportunities for the industry brought by the new entrepreneurship environment and contract manufacture outsourcing industry.

14:30-15:00	Opening Ceremony
15:00-15:40	Topic: The Challenges and Opportunities facing Beijing Biopharmaceutical Industry in Its Leap-forward Development ——Gou Zhongwen, Deputy Mayor , Beijing Municipality
15:40-16:20	Topic: The Contribution and Impact that Biopharmaceutical Industry Brings to Regional Development ——Mervyn Turner, Chief Strategy Officer and Global SVP, New Market R &D, Merck Corp
16:20-17:00	Topic: The Impact of Basic National Drug Systems on the Future Development of Pharmaceutical Industry ——Zheng Hong, Director, Department of Pharmaceutical Policy and Essential Drug System under the Ministry of Health, P.R.C
17:00-17:40	Topic: The Global Trends of Pharmaceutical Innovation and Areas of Focus for China in the Future ——A Laureate of Nobel Prize(pending)
18:00-20:00	Dinner



Oct 26, 2010 (Tuesday)

Summit on Beijing Leap-forward Development program for Biopharmaceutical Industry(G20)

Venue: Conference Center, Beijing International Hotel

Tenet:

2010, Beijing government published the “Beijing biopharmaceutical Leap-Forward Development Program”, it will implement for three years, and support the large scale companies in Beijing to grow bigger, promote the innovative companies to expend quicker, and attract more multinational companies to establish sectors in Beijing better, by establishing a coordinative system, setting up industry developing funds, establishing a set of platforms according to the international standards, implementing a serious of promoting methods, and breaking through a few key policies and more, in order to achieve the goal that the total sales income reaches 100 billion RMB till 2012.

2010 is the beginning year and vital year for the Leap-Forward Development Program. This summit will take “Beijing-A Global Biopharmaceutical Innovative City Summit” as the theme, holding the hope of with international vision to integrate global resources to realize the Leap-Forward Development goal. The summit will invite multinational companies, international consulting agency to discuss the important role of the biopharmaceutical industry in building Beijing as a Beijing-A Global Biopharmaceutical Innovative City and advise the ways and actions Beijing should take. The summit also will invite leaders from Beijing Government, G20 companies, life science parks to share the gains and experience during the first year conduction of the Program.

Chairmen: Frank Douglas, President and CEO, BioInnovation Institute in Akron; Chief Scientific Adviser of Bayer Healthcare

Leaders from Beijing Municipal Science and Technology Commission

09:00-09:05

Opening Ceremony——Speeches by Chairmen

09:05-09:35

Keynote Speech: Introduction and Summary about the Leap-forward Development Program of Beijing Biopharmaceutical Industry
——A Leader from Beijing Municipal Science and Technology



	Commission
09:35-10:05	Topic: The Construction and Development of Biopharmaceutical Industry Cluster Across the World ——Edgar G. Hotard , Chairman, Monitor Group
10:05-10:25	Topic: The Role of Roche’s Development in Promoting Basel to Become a World-class Biopharmaceutical City ——Jean-Jacques Garaud, Global Head, Research and Early Development of Roche
10:25-10:45	Topic: Beijing Goes Hand in Hand with Multinational Companies in Leap-forward Development ——Peter Kurtzhals, SVP, Novo Nordisk
10:45-10:50	Coffee Break
10:50-11:10	Panel Discussion: What Should Beijing Do to Assemble Global Resources to Build a Biopharmaceutical Innovative City Moderator: Frank Douglas, President and CEO, the BioInnovation Institute in Akron; Chief Scientific Adviser, Bayer Healthcare Chinese Counselors and Ministers in Global Cities
11:10-11:40	Q&A, Free Discussion
11:40-12:00	Summary by the Mayor
12:00-12:10	Group Photo



Guests confirmed:

Beijing Representatives:

Leaders of Beijing Municipality, Commissions, Bureaus, and Offices.

Leaders from Zhongguancun Commission

Representatives of Global Innovative Pharmaceutical Cities:

Thomas Forest Farb, Technology & Research / Science City, Puerto Rico

Representatives of Industrial Organizations:

John F. Lewis, Vice President & COO, BioOhio

Mourad Nemra, Vice President, BIOPOLE

Representatives from Institutes:

Laurence Patterson, Director and Prof Drug Discovery, The Institute of Cancer Therapeutics University of Bradford

Representatives of Enterprises:

Nahed Ahmed, Vice President, Amgen Inc.

Peter Kurtzhals, SVP, Novo Nordisk

Stephen Henry Friend, President, Sage Bionetworks; former SVP of Merck Co.

Johnson & Johnson, Sanofi-aventis

Canwen Jiang, VP & Head, Genzyme R&D Asia, Genzyme

G20 companies



Oct 26, 2010 (Tuesday)

The 4th Biopharmaceutical Technology Transfer Summit—To Discover Rising Stars in Chinese

Biopharmaceutical Industry

Venue: Conference Center, Beijing International Hotel

Tenet:

Technology transfer is an important way for biopharmaceutical enterprises to achieve rapid development. In recent years, under the impact of financial crisis, multinational companies have adjusted their new drug R&D strategies. The 11th Five-year Plan on National Programs for Major New Drug Creation witnessed the emergence of a great number of excellent results. This submit will analyze and discuss the new opportunities for biopharmaceutical technology transfer and the new models for result export and project import under the context of financial crisis, in a view to facilitate excellent results to be transferred on the global stage. Partners to this submit includes well-known institutes, scaled enterprises, technology transfer institutions, and investment organizations from United States, Germany, Japan, South Korea, and China.

The 1st Session New Opportunities for Technology Transfer

Moderator:

09:00-09:30	Topic: The R&D Strategic Adjustments of Multinational Companies Brought Opportunities for China to Introduce in New Projects ——Chen Li, CEO, Hua Medicine
09:30-10:00	Topic: The Result Translation & Acquisition Platform of Beijing Pharmaceutical Industry —— pending
10:00-10:15	Discussion and Summary
10:15-10:25	Coffee Break

The 2nd Session New Models of Technology Transfer

10:25-10:55	Topic: New Models of Technology Transfer and Result Export in Europe ——Stein Christian, CEO, ASCENION
10:55-11:25	Topic: the new model of the European technology transfer ——Scott Smith, President , Rheumatology and Immunology Branch of Celgene



11:25-11:40	Discussion and Summary
11:40-13:30	Lunch
The 3rd Session Matchmaking between Excellent Results and G20 Enterprises	
Moderator: (TBD)	
13:30-15:00	Topic: Promotion Session for Result Projects, Technological Projects, Enterprising Teams (PPT in both English and Chinese, 10 minutes for each report, 5 minutes for comments, and 2 minutes for questions) (poster display and question answering by result owners) About Variety:
15:00-15:15	Coffee Break (poster display and questions about results)
15:15-16:45	About Technology: (1) Neutralization Antibody Technology Platform – Tainodi (2) Bruce Murdoch, Commercial Director, Stravencon About Teams: (1) Andrew de Guttadauro, SVP, Commerce Department of Western States Biopharmaceuticals, Inc (2) Michael A. Dalrymple, Director, Business Development of MRC Technology
16:45-17:00	Summary
The 4th Session Agreement Signing Ceremony on the Transformation of Recent Biopharmaceutical Results	
	Comment Guests: G20: G20 Enterprises and Other Large-scale Enterprises Research Institutes: School of Pharmaceutical Sciences at Peking University (Technology Transfer Department) Tsinghua University (International Technology Transfer Centre) Academy of Military Medical Sciences (Result Department of the Ministry of Science and Technology) Academy of Military Medical Sciences (Information Centre) Chinese Academy of Medical Sciences (Office of Scientific Research) Institute of Materia Medica, Chinese Academy of Medical Sciences (Office of



Scientific Research)

Chinese Academy of Medical Sciences (Office of Scientific Research)

Beijing University of Chinese Medicine (Office of Scientific Research and Industry Management)

Technology Transfer Institutions:

Modern Medicines Technology Transfer Center of Beijing

Andrew de Guttadauro, SVP, Commerce Department of Western States

Biopharmaceuticals, Inc.

Bruce Murdoch, Commercial Director, Stravencon

MRCT

Government Organs:

Ba Jixing, Director, Biopharmaceutical Department of Beijing Municipal Science and Technology Commission

Xu Zheng, Director, Beijing Major Project Management Office

Li Jianling, Deputy Director, High and New Technology Department of Beijing Municipal Science and Technology Commission

Liu Jun, Director, Beijing Technology Market Management Office



Oct 26, 2010 (Tuesday)

Diagnostic Reagent Industry Seminar

Venue: Conference Center, Beijing International Hotel

Tenet:

At present, the international market of reagents for clinical diagnosis is growing at an annual rate of 3%-5%, and is now in a period of sustained development. FDA has approved nearly 700 varieties of diagnostic reagents, ranking the first in the world. However, according to the recent data published by the International Statistical Classification of Diseases under WHO, there are over 12,000 kinds of diseases. Thus, it is obvious that there is a huge demand for diagnostic reagents over the world. Under the impact of new medical reform, the diagnostic reagent industry in China demonstrated obvious advantages. As the new medical reform goes on, the prevention of diseases has become a priority in the reform of medical industry, which evidently presents new opportunities for the development of "prevention-oriented" diagnostic reagents. To reduce the drug costs and medical care expenses for ordinary people and raise efficiency as much as possible, accurate prevention and diagnosis become especially important. As the national basic healthcare system is fully established, the producers of diagnostic reagents will surely benefit at the first place.

The summit will invite government decision-makers, representatives of industrial alliances, and high-levels of well-known biotech and pharmaceutical companies home and abroad to be present. The summit will proceed the forms of keynote speeches and seminars, and center on topics such as the global status-quo and outlook of diagnostic reagent R&D, the development trends of diagnostic reagent industry and the countermeasures by companies, and the function of government in the development of diagnostic reagent industry, in order to analyze and discuss the ways to better achieve benign development in the diagnostic reagent industry.

Chairmen: Yin Hong Zhang, Chief, the Biological Product Division of the Drug Registration
Department, SFDA

09:00-09:05	Speech by Chairman
--------------------	--------------------

The 1st Session Cooperation and Win-win



9:05-9:30	<p>Keynote Speech: The Status-quo of Chinese Diagnostic Reagent Industry and Important Issues</p> <p>——Bai Dongting, Director, Medical Device Department of National Institute for the Control of Pharmaceutical and Biological Products</p>
9:30-9:55	<p>Topic: The Trends of Diagnostic Reagent Industry Abroad and China in International Perspective</p> <p>——A Representative from US FDA or Roche</p>
9:55-10:05	Coffee Break
10:05-10:45	<p>Panel Discussion: Strengthen Cooperation and Achieve Win-win Situation (stressing international and domestic cooperation in promoting characteristic development of industries)</p> <p>Moderator: Zhang Zhi, Board Chairman, Beijing Kinghawk Pharmaceutical Co., Ltd ; Head, Medical Association of Beijing Economic and Technological Development Zone</p> <p>Invited Guests:</p> <p>Yin Hongzhang, Chief, Biological Product Division of the Drug Registration Department under State Food and Drug Administration</p> <p>Bai Dongting, Director, Medical Device Department of National Institute for the Control of Pharmaceutical and Biological Products</p> <p>Officials of US FDA</p> <p>Representatives of Domestic Companies</p>
10:45-11:10	<p>Topic: To Set up International Platform to Facilitate Enterprises' Development</p> <p>——Tang Weiguo, Board Chairman of Shanghai Kehua Bio-engineering Co., Ltd</p>
11:10-12:00	<p>Panel Discussion: Case Study about KHB's Cooperation with International Diagnostic Reagent Companies (focusing on cases about international cooperation)</p> <p>Moderator: Zhang Zhi, Board Chairman, Beijing Kinghawk Pharmaceutical Co., Ltd; Head, Medical Association of Beijing Economic and Technological Development Zone</p> <p>Invited Guests:</p> <p>Representatives of Multinational Companies such as BioMerieux, Roche, Siemens, Bayer, Abbott, Johnson & Johnson</p> <p>Representatives of Domestic Companies such as KHB and Wantai</p>



12:10-13:30	Lunch
The 2nd Session Enhance Industry-University-Institute Cooperation and Create a Comprehensive Industrial Blueprint	
13:30-13:55	Topic: To Establish International Standards in Diagnostic Reagent Industry, Running although Clinical Phase to Industry ——Kingmed Diagnostics
13:55-14:20	Topic: Combination of Scientific Research and Industry to Break through Technical Bottlenecks ——Xia Ningshao, Professor, School of Life Sciences at Xiamen University
14:20-14:45	Topic: Where is the Way out for Chinese Diagnostic Reagent Companies to Achieve Technical Innovation? ——Ying Xitang, CEO, Beijing Chemclin Biotech Co., Ltd
14:45-15:30	Panel Discussion: To Explore the New Models of Industry-University-Institute Cooperation Moderator: TBD Invited Panelists: Representatives of Institutes Representatives of Companies Representatives of Venture Capitals
15:30-15:40	Coffee Break
The 3rd Session The Outlook and Directions of the Industry	
15:40-16:05	Topic: The Impact of National Prevention and Control Policies on Diagnostic Reagent Industry ——Dong Xiaoping, Director, Division of Science and Technology, Chinese Center for Disease Control and Prevention
16:05-16:30	Topic: New Challenges Posed on Diagnostic Reagent Industry by the Clinical Trial of New Technologies ——Director of the Clinical Trial Department of a Hospital



16:30-16:55	Topic: To Explore the New Model of Third Party Testing ——He Jian, General Manager , Center for Clinical Laboratory Development between Chinese Academy of Medical Sciences and Peking Union Medical College
16:55-17:35	Panel Discussion: Diagnostic Industry Development Trends, Judging from An Angle of Clinical Application Moderator: TBD Invited Panelists: He Jian, General Manager , Center for Clinical Laboratory Development between Chinese Academy of Medical Sciences and Peking Union Medical College Zhou Chi, General Manager , Beijing IPE Biotechnology Co., Ltd Experts from US Center for Disease Control and Prevention Dong Xiaoping, Director, Division of Science and Technology, Chinese Center for Disease Control and Prevention Director of the Clinical Trial Department of a Hospital
17:35-17:40	Summary by Chairman



Oct 26, 2010 (Tuesday)

ABO Global Partnership Meeting 2010

Venue: Beijing International Hotel Convention Center

Tenet:

As a gala event of the R&D service industry, ABO Global Partnership Meeting 2010 has successfully held for two years and the ABO Global Partnership Meeting 2010 takes “Building High-End Platform, supporting Innovative Development” as the theme, will invite policy-makers, industry alliance representatives, and leaders from top domestic and international pharmaceutical and biotech companies, to discuss the hot spots in biopharmaceutical industry innovation and development.

The meeting will be featured in forms of keynote speeches, panel discussions and one-on-one meetings, to keep you current with the current research situation and development of global biopharmaceutical companies, development directions of domestic pharmaceutical enterprises, and the establishment of platforms promoting the leap-forward development of pharmaceutical enterprises.

Chairman:

Nahed Ahmed, Vice President, Amgen Inc.

Xin-Liang Shen, Chairman of ABO Executive Committee, General manager, Beijing Vigoo Biologicals

Session One: Enhancing international capability, participating in cooperation of international innovation

Moderators:

Stephen Henry Friend, President, Sage Bionetworks, Former SVP of Merck Co.

Frank Jiang, Vice President & Head of R&D in Asia, Sanofi-Aventis Group

09:00-09:10	Opening Remarks by Chairmen
09:10-09:30	Keynote Speech: Challenges and opportunities – condition and development of the global pharmaceutical R&D service industry ——Lee E. Babiss, Executive Vice President, PPD
09:30-09:50	Keynote Speech: The R&D strategy of International pharmaceutical enterprises in China ——Stephen Henry Friend, President, Sage Bionetworks, Former SVP of Merck Co.



09:50-10:20	Panel Discussion: The development strategy and the policy choice of CRO in China of multinational companies Moderator: Ling Zhen, Chinese Area General Manager, Quintiles Panelist: Francis L. Tse, VP of Institutes for Biomedical Research, Novartis Lee E. Babiss, Executive Vice President, PPD Frank Jiang, VP & Head of R&D in Asia, Sanofi-aventis Group Song Li, CEO, Frontage Lab Wei-Wu He, President & CEO, Origene
10:20-10:30	Tea Break
10:30-10:50	Keynote Speech: Establishing service platform, promoting R&D of innovation products by “Union Mechanism” ——Patrick Li, member of ABO Executive Committee
10:50-11:10	Keynote Speech: How do the Chinese GLP integrate with American GLP ——Byungja Marciante, Investigator & Assistant Director US - FDA Shanghai Office
11:10-11:40	Panel Discussion: How do CRO promote innovative product internationalization Moderator: Bao-Ping Wang, VP, Novo Nordisk Panelist: Yue Wu, CEO, Crown Bioscience, Inc. Bo-Liang Lou, CEO, Pharmaron Byungja Marciante, Investigator & Assistant Director US-FDA Shanghai Office Ying Wang, Head of Toxicology, Johnson & Johnson Ge Li, Chairman, Wu Xi AppTec Wei-Wu He, Chairman & CEO, Origene
11:40-11:50	Summary by Moderator
11:50-13:30	Luncheon

Session Two: Establishing manufacture service platform, Constructing industry development environment

Moderators: James Penak, Director, VaxGen, Inc.

DQ Wang, Director of Innovation Management, Bayer



13:40-14:10	Keynote Speech: The requirements and tactics of Biopharmaceutical CMO ——Rolf Werner, SVP, Boehringer Ingelheim
14:10-14:30	Keynote Speech: Analysis of CMO development mode of international biopharma & China orientation ——Tim Charlebois, SVP, Pfizer
14:30-15:10	Panel Discussion: New CMO development mode of international biopharma & challenges and opportunities of China Moderator: Panelist: Andrew C. Chang, Executive Director, Pharmanet Development Group, Inc. Zhi-liang Li, CEO, Autekbio (Beijing), Inc. Ben Amegadzie, Director, Johnson & Johnson Rolf Werner, SVP, Boehringer Ingelheim Tim Charlebois, SVP, Pfizer John McGrath, SVP, Lonza Group Ltd.
15:10-15:20	Tea Break
15:20-15:40	Keynote Speech: The environment and policy of the development of biopharmaceutical CMO ——Ben Amegadzie, Director, Johnson & Johnson.
15:40-16:00	Keynote Speech: Business mode of biopharma CMO in China ——Lei Sun, COO, Autekbio (Beijing), Inc.
16:00-16:40	Panel Discussion: Break bottleneck of biopharma CMO in China to promote the development of generic drug market Moderator: Panelist: Lei Sun, COO, Autekbio (Beijing), Inc. Chris Chen, COO, Celgen DQ Wang, Dir. of Innovation Management, Bayer Hong-Zhang Yin, Director of Bio-product Division, SFDA
16:40-16:50	Summary by Moderator
16:50-17:00	Summary by Chairman



Oct 27, 2010 (Wednesday)

Biopharmaceutical Policy Interpretation Seminar

Venue: Conference Center, Beijing International Hotel

Tenet:

With the emphasis on the bio-pharmaceutical industry, many national and local policies were gradually published. To ensure the enterprise understand the concrete connotation of each policy better, and take full advantage of each policy, also provide a platform for the enterprises to reflecting their demand, this forum will invite related experts who participated in the policy-making and will take a “one-stop” understand to the policy, try to build communication platform for the leaders from government and enterprises, promoting the enterprises developing smoothly and rapidly so as to promote the leap-forward development of Beijing bio-pharmaceutical industry and support the building of Beijing as a global innovative city.

Chairman:

Interpretation of Hot Pharmaceutical Policies in China

13:30-14:00

Topic: The 12th Five-year Plan on National Programs for Major New Drug Creation
——He Wei, Director, Science and Technology Education Department of Ministry of Health; Director, Implementation and Administrative Office of the National Key Program for New Drug Research and Development

14:00-14:30

Topic: Bidding Procurement—the Construction of Bidding Procurement Platform for Non-profit Drugs
——Liu Xinming, Director, Department of Policies and Regulations under the Ministry of Health

14:30-15:00

Topic: Drug Registration Administration
——Zhang Wei, Head, Drug Registration Department under State Food and Drug Administration



15:00-15:30	Topic: The Impact of New GMP on the Development of Pharmaceutical Industry ——Sun Xianze, Director of the Drug Safety Supervision Office of SFDA Or, Guo Qingwu, Director of Production Supervision under the Drug Safety Supervision Office of SFDA
15:30-16:00	Topic: The Impact resulted from the Modification of Medical Insurance Directory on Enterprises' Development ——Tang Xiaoli, Director of Insurance System Division under the Medical Insurance Office of the Ministry of Human Resources and Social Security
16:00-16:30	Topic: Drug Pricing Regulation ——Guo Jianying, Director, Drug Price Office of Price Department, National Development and Reform Commission Or Bai Huiliang, President, China Non-prescription Medicines Association
16:30-17:00	Topic: The Impact of New Medical Reform on the Development of Pharmaceutical Industry ——Song Ruilin, Executive Director, Medical Policy Research Centre of Chinese Pharmaceutical Association
17:00-17:30	Topic: Operation Policies of Pharmaceutical Industry ——Yu Mingde, President of Chinese Pharmaceutical Enterprises Association
17:30-17:50	Summary and Closing



Oct 27, 2010 (Wednesday)

Antibody Industry Seminar

Venue: Conference Center, Beijing International Hotel

Tenet:

With the developing of modern biotechnology, antibody engineering gradually occupies an important position in the pharmaceutical and biotechnology fields. The antibody drugs had created biggest economic and social benefits through its superiority of natural, high specificity, and low toxic.

The seminar will invite decision makers from government, representatives from industrial alliances, and high-levels from well-known biotech and pharmaceutical companies home and abroad to be present to analyze and discuss issues concerned with the biomedical research innovation and industry development in Beijing and the world. In the form of keynote speeches and workshops, the seminar will center on topics such as the status-quo and trends of global antibody and biotech research and development, the status-quo and trends of antibody industry, and the bottlenecks and ways out for Chinese antibody industry.

Chairmen: Chen Zhinan, Academician, Chinese Academy of Engineering; Professor and Director, Cell Engineering Research Center and the Teaching & Research Office of Cell Biology at the Fourth Military Medical University
Davinder Gill, Vice President, Global Antibody R&D, Pfizer

09:00-09:10

Speech by Chinese Chairman
Speech by Foreign Chairman

The 1st Session Antibody Industry is a Global R&D Hot Spot

Moderator: Shen Beifen, Academician, China Academy of Engineering; Researcher, Institute of Basic Medicine of the Academy of Military Medical Sciences(planned)

09:10-09:40

Topic: Chinese Antibody Industry in Progress
——Chen Zhinan, Academician, Chinese Academy of Engineering; Professor and Director, Cell Engineering Research Center at the Fourth Military Medical University



09:40-10:10	Topic: The Global Market Condition of Antibody Drugs and the Development Trends of the Industry ——Davinder Gill, Vice President, Global Antibody R&D, Pfizer
10:10-10:40	Topic: Policy Administration for Antibody Drugs ——Li Guoqing, Director, Center for Drug Evaluation, SFDA
10:40-10:50	Coffee Break
10:50-11:20	Topic: The Antibody Drug R&D in China—Experience and Lessons (planned) ——Bai Xianhong, Board Chairman, Biotech Pharma
11:20-12:20	Panel Discussion: How to Break through the Bottlenecks in Chinese Antibody Industry Moderator: Sun Lei, COO of AutekBio Panel Members: Davinder Gill, Vice President of Global Antibody R&D, Pfizer David Robinson, Vice President of Project Management, Merck & Co., Inc Yin Hongzhang, Chief, Drug Registration Department, SFDA Bai Xianhong, Board Chairman of Biotech Pharma Chris Chen, CTO, Celgene Shanghai
12:20-13:30	Lunch
The 2nd Session The Application of Key Technologies to Promote Industry Development	
Moderator: Chen Zhinan, Academician of Chinese Academy of Engineering, Professor and Director of the Cell Engineering Research Center at the Fourth Military Medical University	
13:30-14:00	Topic: Humanized Antibody ——Tarran Jones, Director of Antibody Center of Medical Research Council, MRC
14:00-14:30	Topic: Antibody Technologies to Accelerate the Preclinical Transformation of Antibody Drugs ——Xie Liangzhi, Sino Biological Inc
14:30-15:00	Topic: Technological Development and Establishment of Antibody Fermentation Process and Purification Process ——David Robinson, VP, Project Management, Merck Sharp & Dohme
15:00-15:30	Topic: How to Develop Production Technologies That Suite Large-scale Production ——
15:30-15:40	Coffee Break



15:40-16:10	Topic: Antibody Drug R&D Strategies and the Application of New Technologies ——Dr. Jill Carton, Director, Johnson & Johnson
16: 10-17: 10	Panel Discussion: The Application and Development of New-Generation Antibody Technologies in the Key Links of Antibody Drug R&D Moderator: Xie Liangzhi, Sino Biological Inc Guests: Dr. Jill Carton, Director, Johnson & Johnson Liao Huaxin, Professor of Duke University Carl K. Edwards, III, Ph.D. School of Medicine, Colorado State University Li Ronghao, Jiangsu Hengrui Medicine Co. Ltd Jefferey Chalmers, Professor, Ohio State University



Oct 27, 2010 (Wednesday)

Medical Imaging Industry Seminar

Venue: Conference Center, Beijing International Hotel

Tenet:

Medical device is one of the three pillar sectors of Beijing biopharmaceutical industry and also one of the fastest growing industries. Beijing acquired rapid development in magnetic resonance imaging and now become the major R&D area for production, and sales in China. However, magnetic resonance imaging is not well-developed in Beijing compared with the developed countries. The international famous enterprises in R&D, clinical practice, and manufacturing of magnetic resonance imaging will attend this session to discuss the developing direction of magnetic resonance imaging technology and solve the problems of the industry, with the aim to promote the development of Beijing magnetic resonance imaging industry.

Moderator:

Gao Jiahong, Director, MRI Research Centre at the School of Physics, Peking University
Beijing Pharma and Biotech Centre (BPBC)

13:30-14:00	Topic: The Demand of Clinical Medicine for the Functions of Medical Imaging Products ——Li Kuncheng, Director Imaging Center of Beijing Xuanwu Hospital
14:00-14:30	Topic: The National Requirements on Medical Imaging Products and Development Trends ——Director of Medical Devices, SFDA
14:30-15:00	Topic: The Development Trends of Medical Imaging Technology ——Yuan Chun, Director, Bio-medical Imaging Research Center at Tsinghua University
15:00-15:30	Topic: What is the Medical Imaging strategy in GE ——GE Medical System
15:30-16:00	Topic: ——Sun Qiyin, Board Chairman, Beijing Top Grade Medicine Equipment Co., Ltd



16:00-16:10	Coffee Break
16:10-16:50	Panel Discussion: The Development Directions and Key Links of Medical Imaging Industry
16:50-17:30	Panel Discussion: How to Create Sound Environment for the Development of Medical Imaging Industry



Guests:

Guests from Industry:

GE Medical System

Xue Min, Former General Manager, Siemens Mindit Magnetic Resonance Ltd

Sun Qigen, Board Chairman, Beijing Top Grade Medicine Equipment Co., Ltd

Xie Yufeng, General Manager, Beijing Wandong Medical Equipment Co., Ltd

Hu Hai, General Manager, Beijing Sinopharm Hundric Medline Info-Tech. Co., Ltd

Yu Honglin, General Manager, Beijing Aerospace Zhongxing Medical System

Zhang Songgen, Board Chairman, TEKNOVA Medical Systems Ltd

Guests from Institutes:

Gao Jiahong, Director, MRI Research Centre at the School of Physics, Peking University

Yuan Chun, Director, Bio-medical Imaging Research Center at Tsinghua University

Wang Xiaoqing, Member, China Association for Medical Devices Industry

Li Kuncheng, Director, the Imaging Center of Beijing Xuanwu Hospital

Vice President or Director of the Imaging Department of Beijing Tiantan Hospital

Director of the Imaging Department of Beijing Jishuitan Hospital

Guests from Administrations:

Zhang Zhaofeng, Director of the Biopharmaceutical Office of Social Development Department, The Ministry of Science and Technology

Director of Medical Devices, SFDA

Zhao Yixin, President, China Association for Medical Devices Industry

Liu Yi, Director General, Beijing Institute of Medical Device Testing

Biopharmaceutical Department of Beijing Municipal Science and Technology Commission

Advanced Manufacturing and Automation Department of Beijing Municipal Science and Technology Commission

Office of Major Projects of Beijing Municipal Science and Technology Commission

Guests from Science Parks::

Chief of Daxing Medical Device Industrial Base

Director of Medical Devices of Beijing Economic and Technological Development Zone



Oct 27, 2010 (Wednesday)

Seminar on the Global Trends and Opportunities for Generic Drugs

Venue: Beijing International Hotel

Tenet:

Generic drug is an effective way for reducing state medical expenditures and enlarging industry scale. Recently, the Chinese government has carried out many projects on R&D and industrialization on generic drug. The Beijing Leap-Forward Development Program also takes generic drug as one of major development tendencies. Try to plan technical roadmap and find out key technology and constraints is important for the generic drug.

The 1st Session The Development Strategies of Generic Drug Companies

Moderator: (TBD)

13:30-13:40

Introduction to the Meeting and Guests by Moderator

13:40-14:10

The Global Development Trends of Generic Drugs
——TEVA

14:10-14:40

China Generic Drug, Trends and Opportunities
——Song Li, Chairman and CEO, Frontage Laboratories, Inc.

14:40-14:50

How Can Chinese Generic Drugs Expand on International Market –
——Huahai Pharmaceutical / Beijing Second Pharmaceutical

Coffee Break

The 2nd Session Generic Drug R&D Strategies

14:50-15:20

Lecture I: Technical Route Design in the R&D Process of Generic Drugs

15:20-15:50

Lecture II: Patent Risk Aversion in the R&D Process of Generic Drugs

15:50-16:20

Topic: The Policies, Regulations, and Technical Requirements on Generic Drugs
——Head of the Evaluation Department of Center for Drug Evaluation, SFDA

16:20-16:50

Lecture III: Composition of DMF, CMC, and Other Related Documents in the International Registration of Generic Drugs

16:50-17:20

Lecture IV: Composition of DMF, CMC, and Other Related Documents Required by US FDA in the International Registration of Generic Drugs II



17:20-17:50	Lecture V : Composition of Documents Required by EMEA in the Registration of Generic Drugs ——Douglas B. ANDREW, CEO, Stravencon
17:50-18:00	Discussion and Exchange
	Guests: Wu Xibing, Board Chairman, Beijing Odyssey Chemicals Co., Ltd Wang Jingang, General Manager, Beijing CoSci Med-Tech Co.,Ltd Tian Shuyan, President, Beijing Yiling Pharmaceutical Institute Israeli Generic Drug Company Li Zhiliang, CEO, AutekBio Huang He & Chu Aiping, General Manager, Beijing Winsunny Pharmaceutical Co., Ltd Shi Hepeng, General Manager, Beijing Haiyan Pharmaceutical Co., Ltd of Yangtze River Pharmaceutical Group Wu Wenduo, General Manager, Beijing Second Pharmaceutical Co., Ltd Li Song, Professor, Institute of Toxic Drugs under Academy of Military Medical Sciences Wang Xiaoliang, Director, Institute of Materia Medica, Chinese Academy of Medical Sciences Sun Congxin, General Manager, China Pharmaceutical R&D Center Co., Ltd Huo Xiumin, Head, Chemical Department of Center for Drug Evaluation, SFDA Zhu Yan, Director, Raw Medicine Evaluation Centre, National Institute for the Control of Pharmaceutical and Biological Products Douglas B. ANDREWS, CEO, Stravencon



Oct 27, 2010 (Wednesday)

The 3rd BioCapital Summit

Venue: Conference Center, Beijing International Hotel

Tenet:

Financing is the bottleneck which restricts the Leap-Forward Development Program. This summit, with the “develop multi-dimensional financing channel, promote Leap-Forward Development Program” as the theme, will invite authorities from financial regulation, financial service, government department, investment organization and bio-pharmaceutical enterprises from Beijing Banking Regulatory Bureau, Banking Management Department of People's Bank of China, Acorn Campus Shanghai Management Co., Ltd, Morgan Group, Goldman Sachs Group, etc. Topics to discuss include how to expand the financing channel, get the breakthrough of financing bottleneck restraint, accelerate the connection between capital and industry, and create investment and financing environment preferential for Beijing bio-pharmaceutical industry, centering on “use financial leverage, accelerate independent innovation”, “science and technology promote innovation of financial products”, “seek new mechanism for high-tech enterprises’ credit capacity evaluation, get the breakthrough of financing bottleneck restraint of small and medium bio-pharmaceutical enterprises”, “new mechanism exploring in the investment and financing environment of Beijing bio-pharmaceutical industry and government equity investment”, “international venture capital approach”, “closely combination among Industry Government University, Research and Business”.

Co-Chairmen: Li Zhenfu, CEO, Direct Forex LLC

Zhang Weiwei, Chairman, Sino-US Biopharmaceutical and Healthcare Fund

09:00-09:10

Speeches by Chairmen

——Li Zhenfu, CEO, Direct Forex LLC

The 1st Session To Establish Financial Chains for R&D and Industrialization in China

Moderators: Li Zhenfu, CEO, Direct Forex LLC

09:10-09:30

Keynote Speech: Risk Analysis of Biopharmaceutical Venture Capitals in China

——Li Zhenfu, CEO, Direct Forex LLC

09:30-09:50

Keynote Speech: GEM Board, An Opportunity to Be Listed



	<p>——China Securities Regulatory Commission</p> <p>Or:</p> <p>Keynote Speech: M&A Strategies That Multinational Companies Applied in China</p> <p>——CEO of a Multinational Company</p>
09:50-10:40	<p>Topics:</p> <ol style="list-style-type: none">1) What Are the New Models of Biopharmaceutical Venture Capitals?2) Compare the Past, Present, and the Future of Biopharmaceutical Venture Capitals in the US with Those in China?3) What Are the Strength, Weakness, Challenges, and Opportunities for Chinese Biopharmaceutical Venture Capitals? What Strategies and Measures Shall We Take Accordingly?4) To Establish Financial Chains for R&D and Industrialization in China: What Are the Problems and How to Achieve Something?
10:40-10:50	Coffee Break
10:50-11:10	<p>Keynote Speech: How Pharmaceutical Enterprises Should Get Well-prepared Financially</p> <p>——A Senior Financial Analyst</p>
11:10-11:30	<p>Keynote Speech: Other Fund Investment Cases</p> <p>——Qiming Weichang Venture Capital Management (Shanghai) Company Limited</p> <p>Or:</p> <p>Keynote Speech: How to Choose Suitable Securities Trader for An Enterprise</p> <p>——Investment Bank</p>
11:30-12:20	<ol style="list-style-type: none">1) How Can the Capitals, Management Skills, Talents, and Projects of International Biopharmaceutical Venture Capitals Land in China Successfully?2) How Can Chinese Biopharmaceutical Companies Get into Wall Street Stock Market Efficiently at a Low Cost?
12:20-13:30	Lunch



The 2nd Session To Explore the New Mechanism to Evaluate the Credit Capacity of Hi-tech Enterprises so as to Break through the Financial Bottlenecks Facing Medium and Small Biopharmaceutical Enterprises

Moderators: Zhang Zegong, Deputy Director, Beijing Pharma and Biotech Center (BPBC)
Banking Management Department of People's Bank of China

13:30-13:50	Keynote Speech: Financial Products Related to Biopharmaceutical Innovation ——Commercial Bank
13:50-14:10	The Achievement Publication and Certification Ceremony of the First Pilot Financial Institutions of Financial Solutions Moderator: Certifying Guests:
14:10-16:00	Project-Capital Matchmaking To elect excellent projects as examples, invite banker and investors to give comments, and conduct in-depth discussions on the companies' characteristics and financial channels.